Can cosentyx affect liver function over time?

What are the long-term liver function effects of Cosentyx?

Cosentyx, also known as secukinumab, is a medication used to treat various autoimmune diseases, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. As with any long-term medication, concerns about liver function are valid, especially since Cosentyx is administered via injection or infusion.

According to the FDA labeling [1], clinical trials have demonstrated that Cosentyx does not cause significant liver function abnormalities or damage. However, the FDA requires postmarketing surveillance to monitor potential liver-related effects. As a result, a pharmacovigilance program has been established to track any adverse events associated with Cosentyx.

A review by Drugs.com [2] indicates that liver function tests (LFTs) are monitored regularly during Cosentyx treatment. These tests assess liver enzymes and overall liver health. While some patients may experience elevated LFTs, this does not necessarily indicate liver damage or function impairment. In most cases, LFTs return to normal without interruption in therapy.

What is the risk of liver damage from Cosentyx?

Studies have not established a significant risk of liver damage or failure due to Cosentyx. A systematic review and meta-analysis published in the Journal of Clinical Rheumatology [3] concluded that the evidence does not suggest a notable increased risk of liver damage or elevated LFTs in patients treated with secukinumab.

Can pre-existing liver conditions affect Cosentyx treatment?

Cosentyx may be contraindicated or approached with caution in patients with pre-existing liver conditions, such as hepatitis or liver cirrhosis. In such cases, careful monitoring of liver function is essential. The drug's labeling [1] advises healthcare providers to use caution when administrating Cosentyx to patients with moderate to severe liver impairment.

In summary, while concerns surrounding Cosentyx's long-term liver function effects exist, clinical trials have not demonstrated a significant risk of liver damage or impairment. Regular liver function monitoring remains essential during treatment.

References:
[1] Cosentyx (secukinumab) Prescribing Information. Novartis Pharmaceuticals. (2022)
[2] Drugs.com. Information and reviews about Cosentyx. (2022)
[3] Systematic review and meta-analysis: Safety of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases. (2020)

Sources:
- [1] Cosentyx (secukinumab) Prescribing Information
- [2] Drugs.com
- [3] Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases